Vertex Pharmaceuticals Incorporated (0QZU.L)
0QZU.L Stock Price Chart
Explore Vertex Pharmaceuticals Incorporated interactive price chart. Choose custom timeframes to analyze 0QZU.L price movements and trends.
0QZU.L Company Profile
Discover essential business fundamentals and corporate details for Vertex Pharmaceuticals Incorporated (0QZU.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
10 Nov 2014
Employees
6.10K
Website
https://www.vrtx.comCEO
Reshma Kewalramani FASN,
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
0QZU.L Financial Timeline
Browse a chronological timeline of Vertex Pharmaceuticals Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 9 Feb 2026
Upcoming earnings on 3 Nov 2025
Earnings released on 4 Aug 2025
EPS came in at $4.52 surpassing the estimated $4.27 by +5.85%, while revenue for the quarter reached $2.94B , missing expectations by -3.69%.
Earnings released on 5 May 2025
EPS came in at $4.06 falling short of the estimated $4.25 by -4.47%, while revenue for the quarter reached $2.77B , missing expectations by -5.31%.
Earnings released on 10 Feb 2025
EPS came in at $3.50 falling short of the estimated $4.02 by -12.94%, while revenue for the quarter reached $2.89B , beating expectations by +3.84%.
Earnings released on 5 Nov 2024
EPS came in at $4.01 falling short of the estimated $4.08 by -1.72%, while revenue for the quarter reached $2.77B , beating expectations by +3.22%.
Earnings released on 2 Aug 2024
EPS came in at -$13.92 falling short of the estimated -$11.63 by -19.76%, while revenue for the quarter reached $2.65B , missing expectations by -0.68%.
Earnings released on 7 May 2024
EPS came in at $4.21 surpassing the estimated $4.07 by +3.44%, while revenue for the quarter reached $2.69B , beating expectations by +4.10%.
Earnings released on 5 Mar 2024
EPS came in at $3.71 falling short of the estimated $4.07 by -8.85%, while revenue for the quarter reached $2.52B , beating expectations by +0.31%.
Earnings released on 13 Dec 2023
EPS came in at $3.97 surpassing the estimated $3.93 by +1.02%, while revenue for the quarter reached $2.48B , missing expectations by -0.83%.
Earnings released on 2 Aug 2023
EPS came in at $3.52 falling short of the estimated $3.86 by -8.81%, while revenue for the quarter reached $2.49B , beating expectations by +2.66%.
Earnings released on 2 May 2023
EPS came in at $2.69 falling short of the estimated $3.01 by -10.63%, while revenue for the quarter reached $2.35B , beating expectations by +0.71%.
Earnings released on 8 Feb 2023
EPS came in at $3.15 falling short of the estimated $3.53 by -10.76%, while revenue for the quarter reached $2.25B , missing expectations by -2.36%.
Earnings released on 31 Oct 2022
EPS came in at $3.59 falling short of the estimated $3.61 by -0.55%, while revenue for the quarter reached $2.27B , beating expectations by +1.75%.
Earnings released on 27 Jul 2022
EPS came in at $3.13 falling short of the estimated $3.47 by -9.80%, while revenue for the quarter reached $2.15B , beating expectations by +0.90%.
Earnings released on 27 Apr 2022
EPS came in at $2.96 falling short of the estimated $3.57 by -17.09%, while revenue for the quarter reached $2.08B , beating expectations by +0.12%.
Earnings released on 31 Jan 2022
EPS came in at $3.00 falling short of the estimated $3.29 by -8.81%, while revenue for the quarter reached $2.06B , beating expectations by +3.03%.
Earnings released on 2 Nov 2021
EPS came in at $0.26 , while revenue for the quarter reached $1.81B .
Earnings released on 30 Sept 2021
EPS came in at $3.28 , while revenue for the quarter reached $1.99B .
Earnings released on 31 Mar 2021
EPS came in at $2.49 , while revenue for the quarter reached $1.74B .
Earnings released on 31 Dec 2020
EPS came in at $2.30 , while revenue for the quarter reached $1.63B .
Earnings released on 30 Sept 2020
EPS came in at $2.53 , while revenue for the quarter reached $1.54B .
0QZU.L Stock Performance
Access detailed 0QZU.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.